Le Goux Constance, Vacher Sophie, Pignot Géraldine, Sibony Mathilde, Barry Delongchamps Nicolas, Terris Benoit, Piaggio Eliane, Zerbib Marc, Damotte Diane, Bieche Ivan
Department of Genetic, Institut curie, Unité de pharmacogénomique, Service de génétique, Paris, France.
Department of Urology, Institut Paoli-Calmettes, Service d'Urologie, Marseille, France.
Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.
Immunotherapy for bladder cancer has given promising results. Here we aimed to evaluate the possible involvement and prognostic value of 33 genes involved in the immune response during bladder carcinogenesis. Expression levels were assessed by quantitative real-time RT-PCR in normal and tumor human bladder samples. Immunohistochemistry was performed to evaluate the protein expression of 2 genes and relation of the mRNA and protein levels was analyzed. Tumors were obtained from 154 patients (83 with muscle-invasive bladder cancer [MIBC] and 71 non-MIBC [NMIBC]) who underwent transurethral bladder resection or radical cystectomy between 2002 and 2006. All patients signed an informed consent. Results of molecular analyses were coupled with survival analyses. Overall, 25 genes (75.8%) were significantly overexpressed in MIBC and 15 (45.5%) were deregulated in NMIBC as compared with normal tissue. On multivariate analysis, risk of NMIBC recurrence was increased with high / ratio and overexpression of (p = 0.016 and p = 0.0039, respectively). In MIBC, a molecular signature of 3 genes () was significantly associated with prognosis in terms of recurrence-free and overall survival (p = 0.0007 and p = 0.007). RT-PCR findings were confirmed by immunohistochemistry for CD8 and FOXP3, with high association between mRNA and protein levels. Finally, risk of recurrence of non-muscle-invasive bladder cancer was increased with high / ratio and overexpression. We identified a 3 gene molecular signature associated with prognosis of muscle-invasive bladder cancer. These results confirm the useful role of immune checkpoints in bladder carcinogenesis and suggest targets for therapy.
膀胱癌免疫疗法已取得了令人鼓舞的成果。在此,我们旨在评估33个参与膀胱癌发生过程中免疫反应的基因的可能作用及预后价值。通过定量实时逆转录聚合酶链反应(RT-PCR)评估正常和肿瘤人类膀胱样本中的基因表达水平。进行免疫组织化学以评估2个基因的蛋白表达,并分析mRNA和蛋白水平之间的关系。肿瘤样本来自2002年至2006年间接受经尿道膀胱切除术或根治性膀胱切除术的154例患者(83例肌层浸润性膀胱癌[MIBC]和71例非肌层浸润性膀胱癌[NMIBC])。所有患者均签署了知情同意书。分子分析结果与生存分析相结合。总体而言,与正常组织相比,25个基因(75.8%)在MIBC中显著过表达,15个基因(45.5 %)在NMIBC中表达失调。多因素分析显示,NMIBC复发风险随着高 / 比值和 的过表达而增加(分别为p = 0.016和p = 0.0039)。在MIBC中,3个基因( )的分子特征在无复发生存率和总生存率方面与预后显著相关(p = 0.0007和p = 0.007)。RT-PCR结果通过CD8和FOXP3的免疫组织化学得到证实,mRNA和蛋白水平之间具有高度相关性。最后,非肌层浸润性膀胱癌的复发风险随着高 / 比值和 的过表达而增加。我们确定了一个与肌层浸润性膀胱癌预后相关的3基因分子特征。这些结果证实了免疫检查点在膀胱癌发生中的重要作用,并提示了治疗靶点。